Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford Genome Sciences and Medarex have entered into a strategic collaboration to discover and develop new human antibody therapeutics for the treatment of cancers, including colorectal cancer.
Subscribe to our email newsletter
The collaboration combines Oxford Genome Sciences’ (OGeS) ability to discover novel targets for oncology with Medarex’s expertise in the development of fully human antibody therapeutics.
The companies will discover, develop and commercialize therapeutic antibodies on a 50:50 basis. Other financial terms of the agreement were not disclosed.
During the initial phase of the collaboration, OGeS intends to provide novel colorectal cancer targets, against which Medarex expects to generate fully human monoclonal antibodies using its proprietary UltiMAb human antibody development system.
“I am extremely excited about our partnership with Medarex, a leader in the development of human antibody therapeutics. Their expertise in combination with the unique targets from our OGAP database give me great confidence that we can develop new and improved treatment options for patients with colorectal cancer,” said Dr Christian Rohlff, CEO of OGeS.